Preoperative autologous blood donation (PAD) boomed in popularity during the 1980s and 1990s after it was recognized that HIV and HCV could be transmitted by allogeneic blood transfusion. 1 At the peak of this public health concern, the World Marrow Donor Association (WMDA) and the National Marrow Donor Program (NMDP) produced guidelines stating that all bone marrow harvest centers should collect preoperative autologous blood for transfusion back into volunteer donors during or after their harvest procedure. [2] [3] [4] [5] In the past decade, with significantly reduced risk of allogeneic transfusion-transmitted disease, recognition of the risks associated with autologous transfusion, multiple landmark studies supporting restrictive transfusion thresholds, increased non-transfusion management options, and increased focus on constraining healthcare costs, there has been a marked decline in the practice of PAD. 1 However, PAD among healthy bone marrow donors remains a widespread practice. To better understand the benefits and harms to our institution's volunteer marrow donor population, we obtained Institutional Review Board permission to retrospectively review the records of volunteer bone marrow donors undergoing marrow harvest at our large academic medical center between January 2009 and December 2013 (Harvard Committee on the Use of Human Subjects, Protocol# 2014P000352).
As standard practice at this institution, baseline hematocrit concentration (HCT) was checked at the time of donor medical evaluation,~3-4 weeks before bone marrow donation. Per NMDP guidelines, all donors were counseled at this time to donate 0, 1 or 2 units of autologous blood. The number of autologous units donated depended solely on the number of cells the transplant center requested and the projected harvest amount. Donors were then usually prescribed oral ferrous sulfate tablets to take for 3-4 weeks before the harvest.
Bone marrow harvests were performed by a trained hematologist in the operating room under general anesthesia (with the exception of a single spinal and a single epidural anesthetic due to patient preference). Marrow was harvested from the posterior iliac crests. Previously collected autologous blood was transfused into the donor during or after the harvest without routinely checking HCT first. All donors were hospitalized after their donation.
The following data were collected, when available, from medical records: patient characteristics, baseline HCT, number of predonated units, pre-procedure HCT, post-procedure HCT, number of units of blood (either autologous or allogeneic) transfused. Descriptive statistics were used to summarize characteristics of the study population. ANOVA with Tukey post hoc analysis was used to determine whether HCT measurement differences were statistically significant among the three groups of volunteers who donated 0, 1 or 2 autologous units. Statistical analysis was done using STATA 13.1 (StataCorp LP, Texas, USA).
154 total donors were identified and all were included in the analysis: donor characteristics are presented in Table 1 . Nineteen volunteers donated no preoperative autologous units, 62 donated one unit, and 73 donated two units. All units of predonated autologous blood were transfused back into donors during and immediately after their procedures.
Mean HCT values were calculated separately for donors who had donated 0, 1 or 2 units of autologous blood (Table 1; Figure 1 ). At the medical evaluation before PAD, baseline HCT values were similar for all groups.
There was a statistically significant difference in the HCT drop from the preoperative evaluation (before PAD) to the morning of bone marrow harvest among the three groups who donated 0, 1 or 2 autologous units as determined by one-way ANOVA (F(2,138) = 20.93, P o 0.0001). This HCT drop was significantly greater in the PAD 1 group compared to the PAD 0 group (2.30 ± 0.723, P = 0.005), in the PAD 2 group compared to the PAD 1 group (1.99 ± 0.483, P = 0.000), and also in the PAD 2 group compared to the PAD 0 group (4.29 ± 0.711, P = 0.000).
The post-procedure HCT (the morning after bone marrow harvest and after all autologous units were transfused) was also significantly different for groups who donated 0, 1 or 2 autologous units (F(2,147) = 4.58, P = 0.0117). Post hoc tests revealed that post-procedure HCT was significantly higher in the PAD 0 group compared with the PAD 1 group (3.01 ± 1.04, P = 0.012). However, there were no statistically significant differences between PAD 0 and PAD 2 groups (1.78 ± 1.02, P = 0.195), or between PAD 1 and PAD 2 groups (1.23 ± 0.661, P = 0.156). Of all 154 donors over 5 years, only one volunteer had a measured post-procedure HCT o21% (thought to be due to a procedure-related complication). Two donors had a HCT o24%, and 7 donors had a HCT o27%. No allogeneic blood was transfused in this population. There were no documented transfusion reactions. Records do not clearly indicate how much total crystalloid or non-blood colloid was given during each admission.
The results of this study contribute to the growing data calling the practice of preoperative autologous blood donation before bone marrow harvest into question. [6] [7] [8] In our population, healthy volunteers who had autologous blood collected before their bone marrow harvest had a lower starting HCT on the day of the harvest. This decreased HCT was related to number of PAD units donated and was statistically significant. Theoretically, PAD is timed such that patients regenerate most of their RBC loss before their scheduled procedure. However, the Hemoglobin and Iron Recovery Study (HEIRS) of 215 healthy blood donors showed that the median time to 80% recovery of initial HB after donation of a full whole blood unit (500 mL) for participants taking iron was 76 days (IQR 20-126); and for participants not taking iron was longer than 168 days (IQR 147 ⩾ 168 days; P o0 .001). 9 This finding helps explain the observed post-PAD day of procedure HCT drop observed in our study. A Cochrane review of 21 randomized control trials evaluating PAD also found that PAD before multiple other surgical procedures resulted in mean reduction of preoperative HB by 1.1 g/dL compared with patients who did not donate autologous units. 10 This pre-procedure relative anemia, if anything, increases the risk of reaching a transfusion threshold.
At the same time, multiple recent landmark trials now support reduced transfusion thresholds and anemia tolerance. 11 No donor in this study reached a HCT concentration considered to be unsafe for healthy adults. Unfortunately, our population did not include volunteers who donated autologous units and then were not transfused, and the volunteers who did not donate autologous units in this study donated significantly less bone marrow than those who did, thus limiting conclusions that can be reached about the association of auto-transfusion with post-procedural HCT values. The data also do not allow for a definitive statement about the frequency at which allogeneic transfusion would be required if PAD and auto-transfusion were not offered.
Every healthy bone marrow donor in our study who donated autologous blood was auto-transfused, exposing them to risk of transfusion-related reactions. Though no reactions were noted, this is not surprising given the overall rate of reactions is very low. Studies show that the rate of transfusion-related reactions -including bacterial infection, clerical errors, administration of incorrect units, and donation-related complications --are similar for autologous and allogeneic blood. 1, 12 Febrile nonhemolytic transfusion reactions, allergic reactions, and transfusion-related acute lung injury have all been reported after autologous blood transfusion as well. 13 With improved donor screening and testing of donated blood, risk of virus transmission in the United States is extremely low at approximately 1 in 1 470 000 units for HIV, 1 in 1 150 000 for HCV and 1 in 1 000 000 for HBV. 14 Automatic transfusion of autologous units may occur due to poorly understood or underestimated risks of auto-transfusion, or hesitation to waste autologous units, which cannot enter the allogeneic blood supply pool if not used by the donor.
Finally, the cost of obtaining, storing and transfusing autologous units was not calculated in this study. However, previous estimates have shown this cost to be significantly higher than for allogeneic units (for example, $68 per allogeneic unit to $4,783 per autologous unit of blood). 15 In conclusion, the practice of PAD in healthy bone marrow donor volunteers is increasingly difficult to defend. In addition to low allogeneic transfusion-transmitted disease risk, similar rates of more common transfusion-related reactions, increasing cost consciousness to healthcare systems, and increasing anemia tolerance with reduced transfusion thresholds, with further evidence of phlebotomy-induced anemia and consistently delayed RBC recovery times, the efficacy is questionable. Automatic referral of all healthy volunteers scheduled for bone harvest may no longer be appropriate.
We encourage further investigation and reconsideration of the practice of PAD in healthy bone marrow donors, and the exploration of non-transfusion alternatives (preoperative iron or erythropoietin). Specifically, data need to be obtained regarding HCT values after high volume harvests in which autologous red cells were not transfused in order to ensure that safe HCT values are maintained. Finally, physicians need education about the shifting risk-benefit balance associated with auto-transfusion.
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No PAD PAD 1 unit PAD 2 units Figure 1 . Mean HCT concentrations before PAD, immediately before bone marrow harvest, and the morning after bone harvest and auto-transfusion.
